GlassScriptPhysician profile
Jennifer Sabuda
NPI 1174830236
$3,013.69
in general payments reported to CMS, 2019-2025
45 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.27 · 2022: $223 · 2023: $233 · 2024: $782 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $274.24 | 2022-2025 | Calquence, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $211.83 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $144.32 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $141.66 | 2022-2025 | |
| Genzyme Corporation | $130.99 | 2024-2025 | |
| Janssen Biotech, INC. | $124.96 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.12 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $103.74 | 2022-2023 | Xarelto |
| Stryker Corporation | $102.27 | 2025 | Augment Injectable |
| Boston Scientific Corporation | $94.10 | 2022 | |
| Abbvie INC. | $93.51 | 2024-2025 | |
| Celgene Corporation | $83.03 | 2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $80.75 | 2021-2025 | Opdivo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.24 | 2022-2023 | Lifevest |
| Astellas Pharma US INC | $74.96 | 2024-2025 | Xtandi, Padcev |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.62 | 2025 | Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $68.52 | 2025 | Zejula, Jemperli |
| Exelixis INC. | $68.23 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $66.93 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Iovance Biotherapeutics, INC. | $61.78 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $56.92 | 2025 | |
| Eisai INC. | $56.61 | 2024-2025 | |
| Daiichi Sankyo INC. | $53.62 | 2024-2025 | Enhertu |
| Sobi, INC | $50.33 | 2024 | |
| Recordati_rare_diseases_inc. | $49.50 | 2024-2025 | Sylvant, Enjaymo |
| Geron Corporation | $47.68 | 2025 | Rytelo |
| Gilead Sciences, INC. | $47.26 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $46.21 | 2024-2025 | Libtayo |
| Deciphera Pharmaceuticals INC. | $42.61 | 2024-2025 | Qinlock, Romvimza |
| Genentech USA, INC. | $42.40 | 2024-2025 | Tecentriq Hybreza, Alecensa, Tecentriq |
| Array Biopharma INC | $37.13 | 2025 | Braftovi |
| Ipsen Biopharmaceuticals, INC | $29.12 | 2025 | Onivyde |
| Amneal Pharmaceuticals LLC | $24.94 | 2024 | Avastin |
| Alexion Pharmaceuticals, INC. | $24.79 | 2025 | Ultomiris |
| Melinta Therapeutics, LLC | $24.37 | 2023 | Rezzayo |
| Stemline Therapeutics INC. | $24.17 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $22.25 | 2025 | Besremi |
| Puma Biotechnology, INC. | $20.62 | 2025 | |
| Servier Pharmaceuticals LLC | $19.62 | 2025 | |
| Rigel Pharmaceuticals, INC. | $17.91 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Kite Pharma, INC. | $17.88 | 2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $17.59 | 2024 | |
| Legend Biotech USA INC. | $16.26 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $15.61 | 2024 | Clonoseq |
| Heartflow, INC. | $15.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Sabuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.